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Hajdu Cheney Syndrome (HCS), Orpha 955, is a rare disease characterized by acroosteolysis, severe osteoporosis, short
stature, specific craniofacial features, wormian bones, neurological symptoms, cardiovascular defects and polycystic
kidneys. HCS is rare and is inherited as autosomal dominant although many sporadic cases have been reported. HCS is
associated with mutations in exon 34 of NOTCH2 upstream the PEST domain that lead to the creation of a truncated
and stable NOTCH2 protein with enhanced NOTCH2 signaling activity. Although the number of cases with NOTCH2
mutations reported are limited, it would seem that the diagnosis of HCS can be established by sequence analysis of
exon 34 of NOTCH2. Notch receptors are single-pass transmembrane proteins that determine cell fate, and play a
critical role in skeletal development and homeostasis. Dysregulation of Notch signaling is associated with skeletal
developmental disorders. There is limited information about the mechanisms of the bone loss and acroosteolysis in
HCS making decisions regarding therapeutic intervention difficult. Bone antiresorptive and anabolic agents have been
tried to treat the osteoporosis, but their benefit has not been established. In conclusion, Notch regulates skeletal
development and bone remodeling, and gain-of-function mutations of NOTCH2 are associated with HCS.
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Disease name/synonyms
Hajdu-Cheney syndrome; Acroosteolysis dominant type;
Serpentine fibula polycystic kidney syndrome; Orpha
number: 955Definition
Hajdu-Cheney syndrome (HCS) is a rare inherited con-
nective tissue disease characterized by acroosteolysis of
hands and feet, developmental defects of bones, teeth
and joints causing distinctive craniofacial and skull
changes, and also manifested by severe osteoporosis and
short stature. The disease was first described by Hajdu in
1948 in a 37 year old accountant who died 12 years later
of severe neurological complications, and the syndrome
was reported further by Cheney in 1965 (Table 1) [1,2].Epidemiology
HCS is a rare disease; less than 100 cases have been
reported, but its exact prevalence is unknown.* Correspondence: canalis@uchc.edu
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Hajdu-Cheney syndrome (HCS) is a rare disease with
autosomal genetic inheritance, although the disease can
also have sporadic presentations. It is characterized by
acroosteolysis of distal phalanges, severe osteoporosis with
fractures, craniofacial and dental abnormalities and short
stature [1-7]. Patients with HCS exhibit prominent skel-
etal features including facial dysmorphisms, craniofacial
defects, such as micrognathia, mid-face flattening and
dental abnormalities. There is high clinical variability and
a phenotypical evolution of the clinical manifestations.
Some signs of the disease, such as synophrys, hypotelor-
ism and epicanthal folds present as early as in the first two
years of life and others become more evident in young
children and adolescents, so that facial features become
coarser over time [7]. Eventually, adult patients develop
classic features of craniofacial dysmorphism characterized
by bathrocephaly with prominent occiput, mild hyperte-
lorism with telecanthus, downslanted eyes with synophrys,
low-set ears, long philtrum, micrognathia with highly
arched palate or cleft palate, and short neck. Acroosteoly-
sis is frequently observed and can present with symptoms
of inflammation, including pain and swelling. Patients
have short and broad digits. Generalized and local joint
hypermobility are reported frequently. Spinal abnormalitiesentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Hajdu-Cheney syndrome clinical features
Craniofacial features Skeletal features Other features
• Facial dysmorphism, micrognathism • Acroosteolysis, fibular deformities,
fractures, joint hyperlaxity
• Short stature, developmental delay
• Open sutures, wormian bones • Short and broad digits • Polycystic kidneys
• Platybasia and basilar invagination • Osteoporosis with fractures • Neurologic symptoms, hearing loss
• Periodontal disease, tooth abnormalities and loss • Vertebral deformities, scoliosis • Congenital heart/vessel defect
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osis, platybasia and basilar invagination. Long bone deform-
ities such as serpentine fibula also are noted [8]. Abnormal
dental eruptions, decay and premature loss of teeth are
common, and patients have a deep voice, hearing loss and
hirsutism. Cardiovascular defects, including patent ductus
arteriosus, atrial and ventricular septal defects, mitral and
aortic valve abnormalities leading to valvular insufficiency
or stenosis have been reported in HCS [9,10]. Respiratory
infections can present in patients with HCS. Platybasia and
basilar invagination are among the most serious complica-
tions of the disease and result in severe neurological prob-
lems, including hydrocephalus, central respiratory arrest
and sudden death. Some patients present with renal cysts
or polycystic kidneys, and serpentine fibula polycystic kid-
ney syndrome seems to be the same disease as HCS.Figure 1 Structure of NOTCH2 and mutations associated with
Hajdu-Cheney syndrome. The extracellular domain (ECD) of Notch
consists of multiple epidermal growth factor (EGF) repeats, upstream the
transmembrane domain (TMD). The intracellular domain of NOTCH2
(NICD) consists of a transcriptional domain formed by the Rbpjκ
association module (RAM) linked to ankyrin (ANK) repeats, and nuclear
localization sequences. The C-terminus contains the proline (P)-, glutamic
acid (E)-, serine (S)-, and threonine (T)-rich motifs (PEST) domain which is
required for the ubiquitinylation and degradation of the NICD. Nonsense
and deletion mutations in exon 34 associated with Hajdu-Cheney
syndrome (HCS) and pointed by the arrow lead to the formation of a
truncated protein consisting of all NOTCH2 sequences necessary for
the formation of the transcriptional complex, but lacking the PEST
domain needed for the ubiquitinylation and degradation of NOTCH2.
As such, a stable and active NOTCH2 protein is synthesized.Aetiology
Over 60 years after the original description, whole exome
sequencing of individuals affected by HCS revealed the
presence of mutations in exon 34, the terminal exon of
NOTCH2. Either nonsense mutations or deletions leading
to a shift in the open reading frame and the creation of a
termination codon in exon 34 of NOTCH2 upstream the
PEST domain are associated with HCS [11-14]. NOTCH2
transcript levels are equivalent and not lower than those
observed in controls, indicating a reduced capacity to acti-
vate the process of nonsense-mediated mRNA decay. This
is common in mutations affecting terminal exons of a
gene. Since the PEST domain contains sequences neces-
sary for the ubiquitinylation and degradation of NOTCH2
in the proteasome, the mutations lead to the accumulation
of a stable protein and persistence of NOTCH2 signaling
since all sequences required for the formation of the Notch
transcriptional complex are upstream the PEST domain
and are therefore preserved (Figure 1). NOTCH2 is located
in Chromosome 1, 1p13 - p11.
It is of interest that somatic NOTCH2 mutations caus-
ing loss of the PEST domain have been identified in B
cell lymphoma, specifically in splenic marginal zone
lymphoma [15-18]. These mutants exhibit enhanced
transactivating activity in Notch reporter assays in vitro
demonstrating that absence of the PEST domain leads to
enhanced Notch activation [15,16]Despite the pronounced skeletal abnormalities reported
in HCS, little is known regarding the mechanisms under-
lying the bone loss. Although the distal phalangeal osteo-
lytic lesions suggest increased localized bone resorption,
there is no information on the mechanisms responsible
for the generalized osteoporosis. The focal osteolysis is
accompanied by neovascularization, inflammation and fi-
brosis [19-21]. Tissue from iliac crest biopsies has been
examined in a small number of cases of HCS and revealed
decreased trabecular bone, normal or increased bone
remodeling, and normal or decreased bone formation
[21-24]. In two published cases, increased number of oste-
oclasts with normal or increased osteoblasts were found
suggesting that increased bone resorption may be respon-
sible for the bone phenotype [21,25]. These observations
are compatible with the known effects of Notch2 on the
murine skeleton. In osteoclast precursors, Notch2 induces
Nuclear factor of T-cells 1 transcription and osteoclasto-
genesis, and this effect could explain the increased bone
remodeling [26,27]. Whether the osteoblast/osteocyte are
also responsible for changes in bone turnover has not
been established.
Mechanisms responsible for the craniofacial develop-
mental abnormalities probably relate to the effects of
Notch on skeletal development, and the short stature
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chondrogenesis. Less is known about potential mecha-
nisms to explain the periodontal disease and tooth loss
and those responsible for the polycystic kidney disease.
Notch plays a role in cardiovascular development and
angiogenesis, and this would explain the congenital heart
defects.
Missense mutations in exon 34 of NOTCH2, upstream
of sequences encoding for the PEST domain, also have
been detected in patients affected by serpentine fibula-
polycystic kidney syndrome and the mutations are similar
to those associated with HCS [4,28,29].
Diagnosis
Patients with HCS have distinct radiologic findings, in-
cluding acroosteolysis of distal phalanges of hands and
feet. Plain radiographs of the skull reveal open sutures,
intra sutural bones, abnormal flattening of the base of the
skull, elongated sella turcica and absent frontal sinuses.
Radiographs of the spine reveal bone loss and fractures. In
addition, bone mineral density can be utilized to deter-
mine the presence of osteoporosis, although caution is
required for its interpretation since diagnostic criteria
established for postmenopausal osteoporosis may or may
not apply. This is the case, for instance, with most forms
of secondary osteoporosis, where a correlation between
bone mineral density and fracture risk has not been estab-
lished [30,31].
Based on a limited number of cases reported so far,
the common pathogenetic mechanism in HCS seems to
involve nonsense or deletion mutations in exon 34 of
NOTCH2, resulting in a protein product lacking the PEST
domain. Based on this information, the diagnosis of HCS
would be carried out by sequence analysis of exon 34 of
NOTCH2. For this purpose, genomic DNA is isolated
from peripheral leukocytes and exon 34 amplified by
polymerase chain reaction (PCR) using specific primers
followed by sequence analysis of the PCR product [32].
Differential diagnosis
HCS can present with a wide range of skeletal and non-
skeletal manifestations so that the differential diagnosis
may include a large array of clinical conditions. Acroos-
teolysis can be secondary to autoimmune disorders, such
as scleroderma, systemic lupus erythematosus, Sjogren’s
syndrome, rheumatoid arthritis and Raynaud’s disease;
frostbite and injuries; neuropathies; diabetes mellitus;
porphyria and psoriasis [19]. Osteoporosis, primary and
secondary, should be considered in the differential diag-
nosis of HCS [33,34]. Werner’s syndrome and progeria,
osteogenesis imperfecta and other rare skeletal disorders,
such as Ehlers-Danlos syndrome, cleidocranial dysplasia,
idiopathic juvenile osteoporosis also form part of the
differential diagnosis [35].Genetic counseling and antenatal diagnosis
Most cases of HCS are sporadic, although in certain fam-
ilies autosomal dominant transmission is found [11-13].
There is limited information on genetic counseling
and antenatal diagnosis regarding HCS. This is in part
because the disease is rare, and because many cases of
HCS are sporadic. In inherited cases, prenatal diagnosis
could entail NOTCH2 gene sequence analysis, although
as indicated under Diagnosis, the number of HCS cases
associated with NOTCH2 mutations is limited and other
gene mutations are possible. There is limited information
about the penetrance of the disease, and it is conceivable
that selected patients presenting with severe idiopathic
osteoporosis are low penetrance cases of HCS.
Management, including treatment of skeletal manifestations
The management of HCS requires a multi-system approach
related to the organs affected by the disease in a given
patient. Although patients develop acroosteolysis and
osteoporosis, the mechanism of the bone loss is not known,
making decisions regarding therapeutic interventions diffi-
cult. The acroosteolysis seems related to an inflammatory
process. There are no controlled trials on the management
of the osteoporosis; only anecdotal cases treated with either
bisphosphonates or teriparatide. Bisphosphonate therapy
(alendronate and pamidronate) alone or in combination
with anabolic therapy with teriparatide has been attempted
for the treatment of the skeletal manifestations of patients
with HCS, but there is no clear evidence that either therapy
is beneficial [36,37]. Teriparatide recently was shown to
increase bone mineral density in a patient with HCS, but
whether bisphosphonates or teriparatide offer fracture pro-
tection is not known [7]. Importantly, long-term activation
of Notch signaling causes osteosarcoma in experimental
mouse models, a potential concern when considering the
use of teriparatide [38].
There is reasonable evidence indicating that activation of
NOTCH2 signaling causes HCS, and NOTCH2 itself could
be a future target for the treatment of the disease. Experi-
mental modalities to control Notch signaling have been
reported, including the use of antibodies to the Notch
extracellular domain or its ligands, and the use of cell
membrane permeable peptides that interfere with the
formation of the Notch transcriptional complex [39,40].
These approaches could form the basis for the develop-
ment of future therapies for HCS. However, reduced Notch
signaling can result in the formation of vascular tumors in
experimental animals [41]. There have been no studies re-
ported in humans exploring these therapeutic approaches
to block NOTCH2 signaling [41].
Prognosis
HCS is a serious disease, but there is limited information
about the overall prognosis of affected patients, and the
Figure 2 Activation of Notch signaling. Notch receptors and
Jagged/Delta ligands are expressed as single-pass transmembrane
proteins. Receptor-ligand interactions lead to the cleavage of the
Notch receptor and release of the Notch intracellular domain (NICD) to
the cytoplasm. NICD translocates to the nucleus and forms a ternary
complex with Rbpjκ and Mastermind-like, displacing transcriptional
repressors and associating with transcriptional activators, and inducing
expression of Notch target genes.
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complications of the disease. The natural evolution of
HCS leads to the development of acroosteolysis and osteo-
porosis with fractures. As a consequence of the fractures,
morbidity and mortality are increased [42]. The prognosis
of patients with HCS is not favorable when there is evi-
dence of neurological impairment. Basilar invagination is
one of the most serious complications of HCS, and can
occur in about 50% of the cases and result in neurological
complications including central respiratory arrest [6]. Due
to the limited number of cases, it is not possible to know
whether lifespan is reduced, although it is reasonable to
believe that patients with severe neurological complica-
tions may suffer from reduced lifespan.
Molecular basis
Bone remodeling consists in the coordinated resorption
and formation of bone, a process that requires the inte-
grated involvement of cells of the osteoclast and osteoblast
lineage and of signals released by these cells [43-48]. Osteo-
clasts are multinucleated cells derived from the fusion of
mononuclear precursors of the hematopoietic lineage. The
formation of osteoclasts requires receptor activator of nu-
clear factor κ-B ligand (RANKL) and macrophage colony
stimulating factor (M-CSF) [49]. Osteoblasts are cells of
mesenchymal origin, and their differentiation is tightly
regulated by specific signals [50-53]. As osteoblasts become
differentiated, they encounter various terminal destinies,
including becoming embedded in distinct lacunae in the
bone matrix as osteocytes, cells that play a fundamental
role in mechanotransduction [54].
Notch 1 to 4 are single-pass transmembrane receptors
that play a critical role in cell fate decisions [55-60]. Notch
has a complex structure, and its extracellular domain
contains multiple epidermal growth factor-like tandem re-
peats upstream a negative regulatory region. Downstream
the transmembrane domain, there is a Notch intracellular
domain (NICD) consisting of an RBPJκ association mod-
ule linked to ankyrin repeats, and together they form the
Notch transcriptional domain. The C terminus contains
the Proline (P), glutamic acid (E), serine (S) and threonine
(T) rich (PEST) domain which is required for the ubiquiti-
nylation and degradation of the NICD (Figure 1). There
are five classic Notch ligands, which are Jagged1 and 2,
and Delta Like1, 3 and 4 [61]. Notch-ligand interactions
result in the proteolytic cleavage and release of the NICD,
which translocates to the nucleus and interacts with
Rbpjκ, and with Mastermind-like proteins to regulate
transcription (Figure 2) [62-65]. This is termed the canon-
ical signaling pathway, which leads to the transcription of
Hairy and enhancer of split (Hes) 1, 5 and 7 and Hes-
related with YRPW motif (Hey) 1, 2 and L [66]. The Notch
non-canonical signaling pathway does not require Rbpjκ
[61,67].Skeletal cells express Notch1, Notch2 and low levels of
Notch3 transcripts [68-70]. Notch regulates cell renewal
in multiple organs and cell systems, and it is involved in
skeletal development and homeostasis, and in osteoblast
and osteoclast differentiation [57,61,71,72]. Transgenic
overexpression of Notch1 NICD in cells of the osteo-
blastic lineage impairs osteoblast differentiation/function
and causes osteopenia [72]. Notch signaling also sup-
presses chondrogenesis [57,73-80]. The effects of Notch in
cells of the osteoblastic lineage are cell-context dependent
and determined by the degree of differentiation of the cells
targeted by Notch. When Notch is activated in undifferen-
tiated cells of the osteoblastic lineage, it suppresses their
progression to maturity and inhibits osteoblast function
leading to the suppression of bone formation and as a
consequence to bone loss [81]. In contrast, activation of
Notch in mature osteoblasts and in osteocytes increases
trabecular bone mass due to suppressed osteoclast forma-
tion and decreased bone resorption [81,82]. Accordingly,
developmental or post-natal inactivation of Notch1 and
Notch2 in osteoblast progenitors enhances cancellous
bone volume by increasing osteoblast number and activity
[57,83].
Most of the studies reported on the function of Notch
in the skeleton have examined Notch1, so that less is
known regarding the function of Notch2, 3 and 4. Notch1
and Notch 2 retain structural similarity, but these recep-
tors have distinct activities, and global null mutations of
either receptor result in embryonic lethality, indicating
that they do not have redundant functions [84-87]. In con-
trast to the inhibitory effects of Notch1 on osteoclastogen-
esis, Notch2 enhances osteoclastogenesis [27,88].
Canalis and Zanotti Orphanet Journal of Rare Diseases 2014, 9:200 Page 5 of 7
http://www.ojrd.com/content/9/1/200Unresolved questions
Current evidence indicates an association between muta-
tions in Exon 34 of NOTCH2 and HCS. However, the
exact mechanisms by which NOTCH2 causes the mani-
festations of HCS are not known. Limited bone histo-
logical analysis has resulted in inconclusive results. It is
not established whether the bone loss is the result of
increased bone resorption, decreased bone formation or
both. As a consequence, it is difficult to make optimal
therapeutic decisions, and it is not known whether anti-
resorptive and anabolic therapy will reduce the incidence
of fractures in patients affected by the disease. Specific
inactivation of NOTCH2 signaling by use of anti-NOTCH2
antibodies or soluble peptides that interfere with the
formation of the transcriptional complex may offer novel
alternative treatments. However, appropriate clinical trials
are necessary to establish their effectiveness and potential
adverse event profile. The pathogenesis of the acroos-
teolysis may be inflammatory leading to localized bone
resorption but necessary studies to establish mechanisms
involved are lacking and need to be conducted.
Mouse models of HCS, where mutations are intro-
duced in Exon 34 of Notch2 upstream the PEST domain
should serve to study the disease, explore mechanisms
involved and ways to reverse phenotypic manifestations.
These should form the basis for a better understanding
of the disease.Conclusions
Genetic mutations causing either gain- or loss-of-function
of various components of the Notch signaling pathway are
associated with diverse skeletal disorders, confirming that
Notch is critical for skeletal development and homeosta-
sis. Findings in human diseases are consistent with results
of numerous pre-clinical studies. Although HCS affects a
limited number of individuals, discovering a cluster of
mutations in a single domain of NOTCH2 in patients with
HCS has advanced our knowledge regarding potential
mechanisms leading to bone loss.
In conclusion, Notch signaling is required for skeletal
development and bone homeostasis and diseases associated
with dysregulation of Notch signaling are uncommon, but
present with severe clinical manifestations.Abbreviations
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